By Puyaan Singh
Jan 7 (Reuters) – Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a call with analysts on Wednesday.
Shares of the company were up 6.6% in extended trade.
The drug, sold under the brand name Yartemlea, treats transplant-associated thrombotic microangiopathy (TA-TMA), a serious complication that can arise after a stem cell transplant, particularly when donor cells are used.
Yartemlea, a monoclonal antibody drug, works by blocking the MASP-2 protein that plays a key role in the immune system.
Last month, Yartemlea became the first treatment to be approved for TA-TMA.
“Across the pivotal clinical trial … median utilization was 8 to 10 vials per treatment course,” Demopulos said on the call, adding that around “11,000 allogeneic (donor cell) transplants are performed each year in the United States.”
“TA-TMA develops in up to 56% of allogeneic transplant recipients,” he added.
The company said it expects a decision from the European medicines regulator in mid-2026.
The company initiated the commercial launch of Yartemlea in the U.S. on January 2, Demopulos said.
(Reporting by Puyaan Singh in Bengaluru; Editing by Sherry Jacob-Phillips)
